triple agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 per cent or higher by RP-HPLC | Tighter grades reported near 98 per cent |
| Identity confirmation | Mass match by LC-MS | Observed mass compared with sequence-derived mass |
| Storage after dissolution | 2–8 °C, protected from light | Short-term use; avoid repeated freeze–thaw |
| Main degradation routes | Hydrolysis, oxidation, aggregation | Backbone and side-chain susceptibility in solution |
| Common diluents | Sterile water or bacteriostatic water | Choice depends on assay and sterility needs |
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
== Background == Following his victory at the Battle of Pelagonia in 1259 AD against an anti-Nicaean coalition, Nicaean emperor Michael VIII Palaiologos was left free to pursue the reconquest of Constantinople, a primary goal of the Byzantine rump states in both Epirus and Asia Minor since 1204. By 1259 the remnants of the Latin Empire were reduced to the city of Constantinople and its immediate environs, cut off from both the remaining Latin states of Greece and from the Nicaeans' Greek rival, the Despotate of Epirus. As early as 1260, Michael Palaiologos attacked Constantinople, as one of the Latin knights taken prisoner in Pelagonia, whose house was within the city walls, had promised to open a gate for the emperor's troops. He failed to do so, and Palaiologos launched an unsuccessful assault on Galata instead. To strengthen his position, Michael concluded an alliance with Genoa in March 1261. In July 1261, as the one-year truce agreed upon after the failed Nicaean siege of 1260 was nearing its end, the general Alexios Strategopoulos was sent with a small advance force of 800 soldiers (most of them Cumans) to keep a watch on the Bulgarians and to reconnoiter the Latin defenses of the city.
The cones are less abundant than rods and come in three types, each contains its own type of iodopsin, the opsins of the cones. The cones mediate color vision, and vision in bright light (day vision).
=== Names === The natural product was named cyclosporin by the German-speaking scientists who first isolated it and cyclosporine when translated into English. Per International Nonproprietary Name (INN) guidelines for drugs, the y was replaced with i so that the INN for the medication is spelled ciclosporin. Ciclosporin is the INN and the British Approved Name (BAN), while cyclosporine is the United States Adopted Name (USAN) and cyclosporin is a former BAN.
Portugal has a literary tradition that predates the Portuguese language going back into the early 13th century. Portuguese literature developed through song as well as the written page known as cantigas. The cantigas drew practitioners from all social ranging from King Denis I to Martin Codax who was a minstrel. The earliest known work of literature produced by a Portuguese is the Ora faz ost'o senhor de Navarra, a cantiga de escárnio e maldizer written in Galician–Portuguese by João Soares de Paiva at around the year 1200. Portuguese literature developed under the influence of both European geopolitical developments and broader European literary traditions. The Hundred Years' War helped foster the development of Portuguese chronicles by Fernão Lopes, which constitute a valuable record of some of Europe's early encounters with peoples beyond the continent. European medieval chivalric literature, together with didactic religious literature transmitted through adaptations and partial translations, contributed to the development of Portuguese poetry in the translated works of Norman French Arturian narratives. Portuguese literature flourished during the Age of Discovery with writers such as Luís Vaz de Camões and António Ferreira. Modern Portuguese literature took shape through the work of Almeida Garrett, one of the founders of Portuguese Romanticism. Portugal has one Nobel Prize–winning author—José Saramago (1998).
=== Etymology and pronunciation === The name "Liliaceae" (English: ) comes to international scientific vocabulary from Neo-Latin, from Lilium, the type genus, + -aceae, a standardized suffix for plant family names in modern taxonomy. The genus name comes from the Classical Latin word lilium, "lily", which in turn came from the Greek leírion (λείριον). Because of the history of Liliaceae, many species such as Watsonia (bugle lily) that were previously classified in this family bear the name 'lily' but are neither part of the genus Lilium, or the family Liliaceae.
Sources: en.wikipedia.org
electron transport chain (ETC) The process by which electrons are transferred from electron donors to electron acceptors via a stepwise series of redox reactions carried out by dedicated enzymes and protein complexes, especially as a component of metabolic pathways which convert chemical energy from food into a form that is readily accessible by the cell. Most electron transport chains begin by oxidizing molecules derived from glycolysis such as NADH and FADH, converting them into a series of intermediate compounds via a specific sequence of independently catalyzed reactions, with the products of the previous reaction used as reactants in the next reaction until ultimately reaching a terminal electron acceptor. The particular compounds used as donors, intermediates, and acceptors vary widely between organisms and cell types; in aerobic respiration, the terminal acceptor is diatomic oxygen (O2), whereas anaerobic respiration uses other acceptors. In all variants, the free energy released by these reactions is coupled to the chemiosmotic pumping of protons (H+) across a membrane in order to generate an electrochemical gradient which is then used to drive the production of ATP, a process known as oxidative phosphorylation. In eukaryotes, electron transport chains are conducted by proteins embedded within the membranes of mitochondria and chloroplasts, while in prokaryotes the relevant proteins are embedded within the cell membrane.
=== AI methods === AlphaFold was one of the first AIs to predict protein structures. It was introduced by Google's DeepMind in the 13th CASP competition, which was held in 2018. AlphaFold relies on a neural network approach, which directly predicts the 3D coordinates of all non-hydrogen atoms for a given protein using the amino acid sequence and aligned homologous sequences. The AlphaFold network consists of a trunk which processes the inputs through repeated layers, and a structure module which introduces an explicit 3D structure. Earlier neural networks for protein structure prediction used LSTM.
where ρ is the resistivity; i.e. the resistance R is inversely proportional to the cross section area S of the resistor. The reason why Poiseuille's law leads to a different formula for the resistance R is the difference between the fluid flow and the electric current. Electron gas is inviscid, so its velocity does not depend on the distance to the walls of the conductor. The resistance is due to the interaction between the flowing electrons and the atoms of the conductor. Therefore, Poiseuille's law and the hydraulic analogy are useful only within certain limits when applied to electricity. Both Ohm's law and Poiseuille's law illustrate transport phenomena.
Early specimens represent birds that were pets or came from menageries. The oldest surviving bird specimens include an African grey parrot once owned by Frances Teresa Stuart (1647–1702) that was buried with its owner in London’s Westminster Abbey. Several mummified ibis and falcons have been recorded from Egyptian tombs dating from 600 to 300 BC. Bird specimens obtained from the 18th century for natural history collections were most often obtained using firearms. Shotguns with "dust" shot were preferred to reduce damage to the specimens. Today, specimens come from a variety of sources. Many (perhaps most) are salvaged from birds killed by window and communications tower strikes, domestic cats, by-catch from fisheries, die-offs from disease, vehicle strikes, and other accidental sources of mortality. However, the world's bird collections have been argued to be inadequate in documenting avian diversity, from taxonomic, geographic, and temporal perspectives, with some parts of tropical regions considered under-represented in particular museums. Underrepresented taxa continue to be actively collected by ornithologists, generally using either firearms or mist-nets. Permitting agencies oversee these activities in most countries.
The Tandem t:slim X2 insulin pump, made by Tandem Diabetes, can be integrated with the Dexcom G6 or Dexcom G7 Continuous Glucose Monitoring Systems to automate glucose regulation. Using real-time glucose data from the CGM, the t:slim X2 uses an algorithm to adjust insulin delivery based on these readings, helping to prevent glucose highs and lows. This integration enables more flexible management of blood sugar levels throughout the day. The t:slim X2 uses two predictive technologies when connected to the Dexcom CGM: Control-IQ and Basal-IQ. Control-IQ is a hybrid closed-loop system that predicts glucose levels up to 30 minutes in advance using Dexcom CGM data. It adjusts basal insulin delivery by increasing, decreasing, or halting insulin delivery as needed to maintain glucose levels within a target range. Additionally, Control-IQ can automatically administer up to one correction bolus per hour if glucose levels are expected to rise. Basal-IQ also uses Dexcom G6 data to predict glucose trends but primarily focuses on preventing lows. It stops insulin delivery if glucose is expected to drop below 4.4 mmol/L (72 mg/dL) and resumes delivery once glucose levels rise. However, Basal-IQ does not administer correction boluses or adjust insulin for elevated glucose levels.
Sources: en.wikipedia.org
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.
Mass spectrometry is the standard check, comparing the measured mass with the mass calculated from the published amino acid sequence. Retention time on HPLC and peptide mapping provide supporting evidence. Sequence-level confirmation separates it from closely related analogues.
Dry powder is chemically stable enough for freezer storage over long periods. In solution, water participates directly in hydrolysis and enables aggregation, so breakdown accelerates. Cold, dark, short-term storage after dissolution reflects that difference.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。